SDZ 216-525
SDZ 216-525
SDZ 216-525 is a chemical compound that has been studied for its potential pharmacological effects. It is primarily known for its role as a selective antagonist of the neurokinin-1 (NK1) receptor, which is a receptor for the neuropeptide substance P. This compound has been of interest in the field of neuropharmacology due to its potential therapeutic applications in treating conditions such as depression, anxiety, and emesis (vomiting).
Pharmacology[edit | edit source]
SDZ 216-525 functions by binding to the NK1 receptor, thereby inhibiting the action of substance P. Substance P is a neuropeptide involved in the transmission of pain and other sensory signals in the central nervous system. By blocking the NK1 receptor, SDZ 216-525 may reduce the effects of substance P, leading to potential therapeutic benefits.
Mechanism of Action[edit | edit source]
The NK1 receptor is a G protein-coupled receptor that, when activated by substance P, can lead to various physiological responses, including pain perception, inflammation, and stress responses. SDZ 216-525, as an NK1 receptor antagonist, prevents substance P from binding to this receptor, thereby modulating these physiological processes.
Therapeutic Potential[edit | edit source]
Research has suggested that NK1 receptor antagonists like SDZ 216-525 could be beneficial in treating:
- Depression: By modulating the stress response and emotional regulation pathways.
- Anxiety: Through its effects on the central nervous system and stress-related neurotransmission.
- Emesis: Particularly in chemotherapy-induced nausea and vomiting, where substance P plays a significant role.
Clinical Research[edit | edit source]
While SDZ 216-525 has shown promise in preclinical studies, its clinical development has been limited. The compound has been primarily used as a research tool to understand the role of NK1 receptors in various physiological and pathological processes.
Safety and Side Effects[edit | edit source]
As with many pharmacological agents, the safety profile of SDZ 216-525 is an important consideration. In preclinical studies, the compound has been generally well-tolerated, but comprehensive clinical safety data are lacking due to its limited progression into clinical trials.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
